Company Description
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases.
The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.
Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies.
In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells.
It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases.
iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Martin Brenner |
Contact Details
Address: 11750 Sorrento Valley Road, Suite 200 San Diego, California 92121 United States | |
| Phone | 979 446 0027 |
| Website | ibioinc.com |
Stock Details
| Ticker Symbol | IBIO |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001420720 |
| CUSIP Number | 451033203 |
| ISIN Number | US4510337086 |
| Employer ID | 26-2797813 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Martin B. Brenner D.V.M., Ph.D. | Chief Executive Officer, Chief Scientific Officer and Director |
| Felipe Duran | Chief Financial Officer |
| Marc Banjak J.D. | Chief Legal Officer |
| Kristi Sarno | Senior Vice President of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 19, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 11, 2025 | 424B3 | Prospectus |
| Feb 10, 2025 | EFFECT | Notice of Effectiveness |
| Feb 10, 2025 | 10-Q | Quarterly Report |
| Feb 10, 2025 | 8-K | Current Report |
| Jan 31, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jan 31, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Jan 30, 2025 | SCHEDULE 13G/A | Filing |